Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form
- Autores
- Prego, Alejo Facundo; Alonso, Guillermo Daniel
- Año de publicación
- 2023
- Idioma
- español castellano
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Trypanosoma cruzi has a complex life cycle, alternating between an insect vector and the human host, with three well-defined stages: epimastigotes, trypomastigotes, and amastigotes. The stages present in humans are bloodstream trypomastigotes, which is the infective but non-replicative form, and amastigotes, the intracellular replicative form, which are the focus of clinical treatments. Currently, there are two drugs used for treatment: benznidazole (Bz) and nifurtimox. These drugs must be metabolized by the parasite, so they can have an effect, and have a high degree of toxicity to the patient, often leading to treatment abandonment. Recently, the presence of dormant amastigotes within infected cells was described, and they are considered one of the possible causes of therapeutic failure due to their low or null metabolic activity, being able to resist Bz treatment, redifferentiate into trypomastigotes, and reinfect, causing disease relapse. Previous studies described a strategy to differentiate trypomastigotes into amastigotes axenically, using an acidic medium, and maintaining them in this state for a short period (10 days). In this study, we describe a new formulation that allows doubling the cultivation time of axenic amastigotes while preserving their ability to differentiate into trypomastigotes and maintaining their infective potential, similar behavior as dormants. Additionally, we observed signs of a more active metabolism in amastigotes obtained from infected Vero cell cultures, as opposed to those obtained through in vitro differentiation. Therefore, it is necessary to expand studies to determine whether using axenic amastigotes as a model for cultured amastigotes is equivalent or if they would exhibit reduced metabolic activity, making them more similar to dormants.
Fil: Prego, Alejo Facundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Alonso, Guillermo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
XXXIV Reunión anual de la Sociedad Argentina de Protozoología
La Plata
Argentina
Sociedad Argentina de Protozoología - Materia
-
DIFERENCIACIÓN CELULAR
AMASTIGOGÉNESIS
METABOLISMO
ENFERMEDAD DE CHAGAS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/242147
Ver los metadatos del registro completo
id |
CONICETDig_95daf093e9b69bcbcde552f42f1ac412 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/242147 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite formPrego, Alejo FacundoAlonso, Guillermo DanielDIFERENCIACIÓN CELULARAMASTIGOGÉNESISMETABOLISMOENFERMEDAD DE CHAGAShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Trypanosoma cruzi has a complex life cycle, alternating between an insect vector and the human host, with three well-defined stages: epimastigotes, trypomastigotes, and amastigotes. The stages present in humans are bloodstream trypomastigotes, which is the infective but non-replicative form, and amastigotes, the intracellular replicative form, which are the focus of clinical treatments. Currently, there are two drugs used for treatment: benznidazole (Bz) and nifurtimox. These drugs must be metabolized by the parasite, so they can have an effect, and have a high degree of toxicity to the patient, often leading to treatment abandonment. Recently, the presence of dormant amastigotes within infected cells was described, and they are considered one of the possible causes of therapeutic failure due to their low or null metabolic activity, being able to resist Bz treatment, redifferentiate into trypomastigotes, and reinfect, causing disease relapse. Previous studies described a strategy to differentiate trypomastigotes into amastigotes axenically, using an acidic medium, and maintaining them in this state for a short period (10 days). In this study, we describe a new formulation that allows doubling the cultivation time of axenic amastigotes while preserving their ability to differentiate into trypomastigotes and maintaining their infective potential, similar behavior as dormants. Additionally, we observed signs of a more active metabolism in amastigotes obtained from infected Vero cell cultures, as opposed to those obtained through in vitro differentiation. Therefore, it is necessary to expand studies to determine whether using axenic amastigotes as a model for cultured amastigotes is equivalent or if they would exhibit reduced metabolic activity, making them more similar to dormants.Fil: Prego, Alejo Facundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Alonso, Guillermo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaXXXIV Reunión anual de la Sociedad Argentina de ProtozoologíaLa PlataArgentinaSociedad Argentina de ProtozoologíaSociedad Argentina de Protozoología2023info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/242147Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form; XXXIV Reunión anual de la Sociedad Argentina de Protozoología; La Plata; Argentina; 2023; 79-802953-5751CONICET DigitalCONICETspainfo:eu-repo/semantics/altIdentifier/url/https://protozoologia.org.ar/wp-content/uploads/PARASITUS-Volumen-2-2023-ISSN-2953-5751.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:00:53Zoai:ri.conicet.gov.ar:11336/242147instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:00:54.016CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
title |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
spellingShingle |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form Prego, Alejo Facundo DIFERENCIACIÓN CELULAR AMASTIGOGÉNESIS METABOLISMO ENFERMEDAD DE CHAGAS |
title_short |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
title_full |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
title_fullStr |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
title_full_unstemmed |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
title_sort |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form |
dc.creator.none.fl_str_mv |
Prego, Alejo Facundo Alonso, Guillermo Daniel |
author |
Prego, Alejo Facundo |
author_facet |
Prego, Alejo Facundo Alonso, Guillermo Daniel |
author_role |
author |
author2 |
Alonso, Guillermo Daniel |
author2_role |
author |
dc.subject.none.fl_str_mv |
DIFERENCIACIÓN CELULAR AMASTIGOGÉNESIS METABOLISMO ENFERMEDAD DE CHAGAS |
topic |
DIFERENCIACIÓN CELULAR AMASTIGOGÉNESIS METABOLISMO ENFERMEDAD DE CHAGAS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
Trypanosoma cruzi has a complex life cycle, alternating between an insect vector and the human host, with three well-defined stages: epimastigotes, trypomastigotes, and amastigotes. The stages present in humans are bloodstream trypomastigotes, which is the infective but non-replicative form, and amastigotes, the intracellular replicative form, which are the focus of clinical treatments. Currently, there are two drugs used for treatment: benznidazole (Bz) and nifurtimox. These drugs must be metabolized by the parasite, so they can have an effect, and have a high degree of toxicity to the patient, often leading to treatment abandonment. Recently, the presence of dormant amastigotes within infected cells was described, and they are considered one of the possible causes of therapeutic failure due to their low or null metabolic activity, being able to resist Bz treatment, redifferentiate into trypomastigotes, and reinfect, causing disease relapse. Previous studies described a strategy to differentiate trypomastigotes into amastigotes axenically, using an acidic medium, and maintaining them in this state for a short period (10 days). In this study, we describe a new formulation that allows doubling the cultivation time of axenic amastigotes while preserving their ability to differentiate into trypomastigotes and maintaining their infective potential, similar behavior as dormants. Additionally, we observed signs of a more active metabolism in amastigotes obtained from infected Vero cell cultures, as opposed to those obtained through in vitro differentiation. Therefore, it is necessary to expand studies to determine whether using axenic amastigotes as a model for cultured amastigotes is equivalent or if they would exhibit reduced metabolic activity, making them more similar to dormants. Fil: Prego, Alejo Facundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina Fil: Alonso, Guillermo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina XXXIV Reunión anual de la Sociedad Argentina de Protozoología La Plata Argentina Sociedad Argentina de Protozoología |
description |
Trypanosoma cruzi has a complex life cycle, alternating between an insect vector and the human host, with three well-defined stages: epimastigotes, trypomastigotes, and amastigotes. The stages present in humans are bloodstream trypomastigotes, which is the infective but non-replicative form, and amastigotes, the intracellular replicative form, which are the focus of clinical treatments. Currently, there are two drugs used for treatment: benznidazole (Bz) and nifurtimox. These drugs must be metabolized by the parasite, so they can have an effect, and have a high degree of toxicity to the patient, often leading to treatment abandonment. Recently, the presence of dormant amastigotes within infected cells was described, and they are considered one of the possible causes of therapeutic failure due to their low or null metabolic activity, being able to resist Bz treatment, redifferentiate into trypomastigotes, and reinfect, causing disease relapse. Previous studies described a strategy to differentiate trypomastigotes into amastigotes axenically, using an acidic medium, and maintaining them in this state for a short period (10 days). In this study, we describe a new formulation that allows doubling the cultivation time of axenic amastigotes while preserving their ability to differentiate into trypomastigotes and maintaining their infective potential, similar behavior as dormants. Additionally, we observed signs of a more active metabolism in amastigotes obtained from infected Vero cell cultures, as opposed to those obtained through in vitro differentiation. Therefore, it is necessary to expand studies to determine whether using axenic amastigotes as a model for cultured amastigotes is equivalent or if they would exhibit reduced metabolic activity, making them more similar to dormants. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Reunión Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/242147 Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form; XXXIV Reunión anual de la Sociedad Argentina de Protozoología; La Plata; Argentina; 2023; 79-80 2953-5751 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/242147 |
identifier_str_mv |
Axenic culture of Trypanosoma cruzi amastigotes as a model for differential metabolic characteristics in the intracellular parasite form; XXXIV Reunión anual de la Sociedad Argentina de Protozoología; La Plata; Argentina; 2023; 79-80 2953-5751 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://protozoologia.org.ar/wp-content/uploads/PARASITUS-Volumen-2-2023-ISSN-2953-5751.pdf |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.coverage.none.fl_str_mv |
Nacional |
dc.publisher.none.fl_str_mv |
Sociedad Argentina de Protozoología |
publisher.none.fl_str_mv |
Sociedad Argentina de Protozoología |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844613796349345792 |
score |
13.070432 |